Drug screening on live cells

LSCCB
Overview

An innovative way to perform ultra-high throughput drug screening (billion compound scale) directly against cancer cells

  • Drug screening on live cells 0
Technical name of innovation
Selection of DNA-encoded library against endogenous membrane proteins
Commercialisation opportunities
Collaboration agreement
Problem addressed

Drug discovery against membrane proteins is highly challening. This innovation enabled the screening of billions of compounds against membrane protein drug targets on cancer cells in just a few hours.

Innovation
  • The membrane protein target is specifically labeled with a DNA tag, which enabled target-specific screning of compound libraries.
  • The screening can be performed in a regular biochemistry laboratory in just a few hours without specialty instrument and facility.
Key impact
  • This innovation facilitated drug discovery against tough membrane protein targets
  • Rapid discovery of drug leads for downstream development.
  • Generally applicable to a wide range of membrane protein targets.
Application
  • Drug discovery
  • Probe discovery

Laboratory for Synthetic Chemistry and Chemical Biology (LSCCB) is an R&D centre funded by Health@InnoHK progamme of Innovation and Technology Commission of  HKSAR. Established in 2020, LSCCB is operated with tripartite joint collaboration of The University of Hong Kong, Imperial College London and Peking University. LSCCB aims at integrating chemical and biomedical sciences to develop new molecular medicines and diagnostic tools for the treatment and analysis of human diseases, in particular, cancer. LSCCB currently assembles more than 20 principal investigators for 4 major research programmes including (a) Synthetic Chemistry; (b) Chemical Biology of Natural Products and Chinese Medicine; (c) Metal Anticancer Medicine, Diagnostics and Theranostics; and (d) Multi-Omics and Innovative Analytical Technologies for InnoHealth.

Enquiry
Related Innovations